Clinical review 131: Gene therapy for thyroid cancer: Where do we stand?

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 7, 2001, Pages 2923-2928

  DeGroot, L J ^a   Zhang, R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CYTOKINE; DNA; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; LYMPHOTACTIN; PROTEIN P53; THYMIDINE KINASE; THYROGLOBULIN; THYROTROPIN RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INJECTION; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VIRUS IMMUNITY;

EID: 0034917625     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.7.7653     Document Type: Review

References (37)

1. - symporter in human glioma cells by adenovirus-mediated gene delivery
2. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
3. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
4. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice
5. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
6. Gene vectors for cytokine expression in vivo
7. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
8. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter
9. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system
10. An adenoviral vector transducing tissue specific expression of thymidine kinase under the control of thyroglobulin promoter has high specificity and low toxicity in gene therapy
11. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status
12. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line
13. Gene therapy for anaplastic thyroid carcinoma with replication-incompetent and -competent adenoviruses
14. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias
15. Overexpression of TTF-1 and PAX-8 restores thyroglobulin gene promoter activity in ARO and WRO cell lines
16. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes
17. Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma
18. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy
19. Genetic immunotherapy for medullary thyroid carcinoma: Destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene
20. Effective genetic therapy of established medullary thyroid carcinoma with murine interleukin-2: Dissemination and cytotoxicity studies in a rat tumor model
21. An adenoviral vector expressing functional heterogeneous proteins-Herpes Simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity in a medullary tumor
22. Effective eradication of established murine tumor with IL-12 gene therapy using a polycistronic retroviral vector
23. Gene-gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors
24. Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin-12 subunits in a rat medullary thyroid carcinoma model
25. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-3, pro-IL-18, and IL-1 converting enzyme cDNA
26. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
27. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus
28. Eradication of murine bladder carcinoma by intratumor injection of a biscistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
29. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
30. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
31. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
32. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma
33. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial
34. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
35. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
36. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
37. CT-guided intratumoral gene therapy in non-small-cell lung cancer